Kamada Ltd. (NASDAQ:KMDA)’s stock price was up 6.1% during trading on Thursday . The company traded as high as $10.00 and last traded at $9.02, approximately 1,512,862 shares changed hands during mid-day trading. An increase of 1,162% from the average daily volume of 119,923 shares. The stock had previously closed at $8.50.

A number of equities analysts recently commented on KMDA shares. Zacks Investment Research cut shares of Kamada from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd. TheStreet raised shares of Kamada from a “c+” rating to a “b-” rating in a report on Wednesday, May 20th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a report on Tuesday, May 19th. ValuEngine lowered shares of Kamada from a “hold” rating to a “sell” rating in a report on Thursday, July 2nd. Finally, BidaskClub lowered shares of Kamada from a “buy” rating to a “hold” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $10.00.

The business’s 50 day moving average price is $8.59 and its two-hundred day moving average price is $7.12. The stock has a market cap of $394.45 million, a P/E ratio of 16.41 and a beta of 1.20.

Kamada (NASDAQ:KMDA) last announced its earnings results on Monday, May 18th. The biotechnology company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The firm had revenue of $33.29 million for the quarter, compared to analyst estimates of $30.78 million. Kamada had a net margin of 16.87% and a return on equity of 16.24%. As a group, equities analysts expect that Kamada Ltd. will post 0.37 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in KMDA. Marshall Wace LLP bought a new stake in shares of Kamada during the 1st quarter valued at about $276,000. UBS Group AG lifted its position in Kamada by 3,140.2% during the 4th quarter. UBS Group AG now owns 66,521 shares of the biotechnology company’s stock valued at $454,000 after acquiring an additional 64,468 shares during the period. Jane Street Group LLC lifted its position in Kamada by 52.8% during the 4th quarter. Jane Street Group LLC now owns 57,872 shares of the biotechnology company’s stock valued at $395,000 after acquiring an additional 19,991 shares during the period. Norges Bank purchased a new position in Kamada during the 4th quarter valued at about $2,740,000. Finally, Ritholtz Wealth Management purchased a new position in Kamada during the 1st quarter valued at about $69,000. 12.91% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Company Profile (NASDAQ:KMDA)

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

Read More: Dividend Achievers

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.